| scholarly article | Q13442814 |
| P50 | author | Jeffrey R Curtis | Q87706464 |
| Daniel H Solomon | Q91503755 | ||
| P2093 | author name string | George Reed | |
| Marc C Hochberg | |||
| Michael E Farkouh | |||
| Jeffrey D Greenberg | |||
| Soko Setoguchi | |||
| Joel Kremer | |||
| Peter Tsao | |||
| P2860 | cites work | Prediction of Coronary Heart Disease Using Risk Factor Categories | Q22241923 |
| Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score | Q24817087 | ||
| Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report | Q27861020 | ||
| Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein | Q29547752 | ||
| Collaborative overview of randomised trials of antiplatelet therapy--I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration | Q29619529 | ||
| The Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI): a review of their usefulness and validity in rheumatoid arthritis | Q33226724 | ||
| EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis | Q33505914 | ||
| Composite scoring--methods and predictive validity: insights from the Framingham Study | Q33717267 | ||
| Cardiovascular morbidity and mortality in rheumatoid arthritis | Q33806651 | ||
| Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis | Q34182804 | ||
| Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomised placebo-controlled trial | Q34327988 | ||
| Increase in cardiovascular and cerebrovascular disease prevalence in rheumatoid arthritis | Q35036976 | ||
| Cardiovascular admissions and mortality in an inception cohort of patients with rheumatoid arthritis with onset in the 1980s and 1990s | Q35554980 | ||
| Disease-modifying antirheumatic drugs are associated with a reduced risk for cardiovascular disease in patients with rheumatoid arthritis: a case control study | Q35605663 | ||
| Patterns of cardiovascular risk in rheumatoid arthritis | Q35638493 | ||
| Increased unrecognized coronary heart disease and sudden deaths in rheumatoid arthritis: a population-based cohort study. | Q36031031 | ||
| Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register | Q36732112 | ||
| European biologicals registers: methodology, selected results and perspectives | Q37224062 | ||
| Immunosuppressive medications and hospitalization for cardiovascular events in patients with rheumatoid arthritis | Q38465160 | ||
| The risk of myocardial infarction and pharmacologic and nonpharmacologic myocardial infarction predictors in rheumatoid arthritis: a cohort and nested case-control analysis | Q40053146 | ||
| Use and misuse of the receiver operating characteristic curve in risk prediction | Q40241086 | ||
| Which HAQ is best? A comparison of the HAQ, MHAQ and RA-HAQ, a difficult 8 item HAQ (DHAQ), and a rescored 20 item HAQ (HAQ20): analyses in 2,491 rheumatoid arthritis patients following leflunomide initiation | Q43613626 | ||
| Anti-tumor necrosis factor-alpha treatment improves endothelial function in patients with rheumatoid arthritis | Q44187483 | ||
| Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study | Q44973310 | ||
| Rheumatoid arthritis versus diabetes as a risk factor for cardiovascular disease: a cross-sectional study, the CARRE Investigation | Q46433523 | ||
| Lipid profiles among US elderly with untreated rheumatoid arthritis--the Third National Health and Nutrition Examination Survey. | Q46838483 | ||
| Prevalence, awareness, treatment, and control of hypertension among United States adults 1999-2004. | Q48342135 | ||
| Contribution of trends in survival and coronary-event rates to changes in coronary heart disease mortality: 10-year results from 37 WHO MONICA project populations. Monitoring trends and determinants in cardiovascular disease. | Q50647592 | ||
| Mortality in early inflammatory polyarthritis: cardiovascular mortality is increased in seropositive patients. | Q50701881 | ||
| Prevalence of high blood cholesterol among US adults. An update based on guidelines from the second report of the National Cholesterol Education Program Adult Treatment Panel. | Q51600159 | ||
| The CORRONA database. | Q52032004 | ||
| Inflammation, insulin resistance, and aberrant lipid metabolism as cardiovascular risk factors in rheumatoid arthritis. | Q53923887 | ||
| Baseline levels of c-reactive protein and prediction of death from cardiovascular disease in patients with inflammatory polyarthritis : A ten-year followup study of a primary care-based inception cohort | Q57804967 | ||
| Model selection for extended quasi-likelihood models in small samples | Q71717250 | ||
| Association between carotid atherosclerosis and markers of inflammation in rheumatoid arthritis patients and healthy subjects | Q73628316 | ||
| Influence of nonclassical cardiovascular risk factors on the accuracy of predicting subclinical atherosclerosis in rheumatoid arthritis | Q80182570 | ||
| Increased coronary-artery atherosclerosis in rheumatoid arthritis: relationship to disease duration and cardiovascular risk factors | Q81300622 | ||
| Relative contribution of cardiovascular risk factors and rheumatoid arthritis clinical manifestations to atherosclerosis | Q81412936 | ||
| P433 | issue | 11 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | circulatory system | Q11068 |
| rheumatoid arthritis | Q187255 | ||
| P304 | page(s) | 1920-1925 | |
| P577 | publication date | 2010-05-05 | |
| P1433 | published in | Annals of the Rheumatic Diseases | Q4767876 |
| P1476 | title | Explaining the cardiovascular risk associated with rheumatoid arthritis: traditional risk factors versus markers of rheumatoid arthritis severity | |
| P478 | volume | 69 |
| Q93083086 | A Multicenter, Randomized, Placebo-Controlled Trial of Atorvastatin for the Primary Prevention of Cardiovascular Events in Patients With Rheumatoid Arthritis |
| Q37450216 | A simple step test to estimate cardio-respiratory fitness levels of rheumatoid arthritis patients in a clinical setting. |
| Q33790971 | Adiponectin and atherosclerosis in rheumatoid arthritis |
| Q48355389 | Aerobic capacity over 16 years in patients with rheumatoid arthritis: Relationship to disease activity and risk factors for cardiovascular disease |
| Q26991828 | Angiotensin II in inflammation, immunity and rheumatoid arthritis |
| Q42378890 | Angiotensin II type 2 receptor (AT2R) as a novel modulator of inflammation in rheumatoid arthritis synovium |
| Q64251395 | Assessment of Cardiovascular Disease Risk and Therapeutic Patterns among Urban Black Rheumatoid Arthritis Patients |
| Q37273794 | Association between low density lipoprotein and rheumatoid arthritis genetic factors with low density lipoprotein levels in rheumatoid arthritis and non-rheumatoid arthritis controls |
| Q28386085 | Association of rheumatoid arthritis susceptibility gene with lipid profiles in patients with rheumatoid arthritis |
| Q33596873 | Associations of smoking and alcohol consumption with disease activity and functional status in rheumatoid arthritis |
| Q31043666 | Can rheumatoid arthritis (RA) registries provide contextual safety data for modern RA clinical trials? The case for mortality and cardiovascular disease. |
| Q38937245 | Cardiovascular Safety of Tocilizumab Versus Tumor Necrosis Factor Inhibitors in Patients With Rheumatoid Arthritis: A Multi-Database Cohort Study |
| Q33713206 | Cardiovascular case fatality in rheumatoid arthritis is decreasing; first prospective analysis of a current low disease activity rheumatoid arthritis cohort and review of the literature |
| Q26851800 | Cardiovascular disease risk amongst African black patients with rheumatoid arthritis: the need for population specific stratification |
| Q28082992 | Cardiovascular disease risk scores in the current practice: which to use in rheumatoid arthritis? |
| Q90673384 | Cardiovascular risk factors' behavior during the early stages of the disease, in Hispanic rheumatoid arthritis patients: a cohort study |
| Q36361147 | Cardiovascular risk in rheumatoid arthritis: comparing TNF-α blockade with nonbiologic DMARDs |
| Q38124279 | Cardiovascular risk in the rheumatic disease patient undergoing orthopedic surgery |
| Q92464764 | Cardiovascular risk management in rheumatoid and psoriatic arthritis: online survey results from a national cohort study |
| Q37956137 | Cardiovascular safety of biologic therapies for the treatment of RA. |
| Q35222947 | Carotid artery plaque in women with rheumatoid arthritis and low estimated cardiovascular disease risk: a cross-sectional study |
| Q36320021 | Challenges of developing a cardiovascular risk calculator for patients with rheumatoid arthritis |
| Q36901936 | Changes in lipoproteins associated with methotrexate or combination therapy in early rheumatoid arthritis: results from the treatment of early rheumatoid arthritis trial. |
| Q49788530 | Comparative Cardiovascular Risk of Abatacept and Tumor Necrosis Factor Inhibitors in Patients With Rheumatoid Arthritis With and Without Diabetes Mellitus: A Multidatabase Cohort Study |
| Q39020908 | Comparison of cardiovascular risk algorithms in patients with vs without rheumatoid arthritis and the role of C-reactive protein in predicting cardiovascular outcomes in rheumatoid arthritis |
| Q33725505 | Concomitant Use of Statins in Tocilizumab-Treated Patients with Rheumatoid Arthritis: A Post Hoc Analysis |
| Q47802987 | Cost-Effectiveness of Cardiovascular Screening in Patients With Rheumatoid Arthritis |
| Q51174739 | Could cardiovascular disease risk stratification and management in rheumatoid arthritis be enhanced? |
| Q34607215 | Disease activity in inflammatory bowel disease is associated with increased risk of myocardial infarction, stroke and cardiovascular death--a Danish nationwide cohort study |
| Q35655764 | Disease activity in rheumatoid arthritis and the risk of cardiovascular events |
| Q36573102 | Disease-modifying antirheumatic drug use and the risk of incident hyperlipidemia in patients with early rheumatoid arthritis: a retrospective cohort study |
| Q36113215 | Dyslipidemia and changes in lipid profiles associated with rheumatoid arthritis and initiation of anti-tumor necrosis factor therapy |
| Q43524523 | Editorial: inflammation, disease-modifying antirheumatic drugs, lipids, and cardiovascular risk in rheumatoid arthritis |
| Q87586879 | Effect of methotrexate use and erythrocyte methotrexate polyglutamate on glycosylated hemoglobin in rheumatoid arthritis |
| Q37372691 | Effects of 6 months of abatacept treatment on aortic stiffness in patients with rheumatoid arthritis. |
| Q38323310 | Effects of TNFα inhibitors on adiposity and other cardiovascular risk factors: implications for the cardiovascular prognosis in patients with rheumatoid arthritis |
| Q54943957 | Effects of tumor necrosis factor inhibitors and tocilizumab on the glycosylated hemoglobin levels in patients with rheumatoid arthritis; an observational study. |
| Q35687532 | Efficacy of inhibition of IL-1 in patients with rheumatoid arthritis and type 2 diabetes mellitus: two case reports and review of the literature |
| Q37930979 | Ethnic differences in cardiovascular risk in rheumatic disease: focus on Asians |
| Q38492012 | Evidence for treating rheumatoid arthritis to target: results of a systematic literature search update |
| Q37132910 | First time myocardial infarction in a rheumatic patient after elective arthroplasty |
| Q24197686 | Fish oil supplements for rheumatoid arthritis |
| Q64105948 | Gender Differences in Cardiovascular Risk Profile in Rheumatoid Arthritis Patients with Low Disease Activity |
| Q36877859 | Hydroxychloroquine Use Is Associated With Decreased Incident Cardiovascular Events in Rheumatoid Arthritis Patients |
| Q35681167 | Hyperlipidemia in rheumatoid arthritis patients in Saudi Arabia. Correlation with C-reactive protein levels and disease activity |
| Q37612713 | IL-32 promoter SNP rs4786370 predisposes to modified lipoprotein profiles in patients with rheumatoid arthritis |
| Q34724972 | Impact of rheumatoid arthritis on receiving a diagnosis of hypertension among patients with regular primary care |
| Q46027578 | Impact of risk factors associated with cardiovascular outcomes in patients with rheumatoid arthritis. |
| Q44485195 | Implication of antithrombotic agents on potential bleeding from endoscopically determined peptic ulcers, incidentally detected as surrogate markers for nsaids-associated ulcers complication |
| Q46337002 | Incidence and Prevalence of Cardiovascular Risk Factors Among Patients With Rheumatoid Arthritis, Psoriasis, or Psoriatic Arthritis |
| Q40061090 | Incidence of comprehensive hospitalization due to infection, cardiovascular disease, fractures, and malignancies in patients with rheumatoid arthritis |
| Q99711818 | Incident arterial vascular events in a cohort of Puerto Ricans with rheumatoid arthritis |
| Q52312175 | Increased cardiovascular risk in rheumatoid arthritis: mechanisms and implications. |
| Q89801661 | Inflammation, Autoimmunity, Infection, and Stroke: Epidemiology and Lessons From Therapeutic Intervention |
| Q57658287 | Link between traditional cardiovascular risk factors and inflammation in patients with early arthritis: Results from a French Multicenter Cohort |
| Q38972344 | Management of Cardiovascular Risk in Patients with Chronic Inflammatory Diseases: Current Evidence and Future Perspectives. |
| Q37975943 | Managing cardiovascular risk in patients with chronic inflammatory diseases. |
| Q37433269 | Marked independent relationship between circulating interleukin-6 concentrations and endothelial activation in rheumatoid arthritis |
| Q36633320 | Monitoring diabetes in patients with and without rheumatoid arthritis: a Medicare study |
| Q40624064 | Monitoring drug and antidrug levels: a rational approach in rheumatoid arthritis patients treated with biologic agents who experience inadequate response while being on a stable biologic treatment |
| Q40815110 | Monocytes from patients with rheumatoid arthritis and type 2 diabetes mellitus display an increased production of interleukin (IL)-1β via the nucleotide-binding domain and leucine-rich repeat containing family pyrin 3(NLRP3)-inflammasome activation: |
| Q44990567 | Multimorbidity in elderly rheumatic patients part 1 |
| Q39225848 | Non-steroidal anti-inflammatory drugs and risk of cardiovascular disease in patients with rheumatoid arthritis: a nationwide cohort study |
| Q38098935 | Novel risk factors for cardiovascular disease in rheumatoid arthritis |
| Q38628320 | Nurses' Role in Cardiovascular Risk Assessment and Management in People with Inflammatory Arthritis: A European Perspective |
| Q36245756 | Obesity and carotid atherosclerosis in African black and Caucasian women with established rheumatoid arthritis: a cross-sectional study |
| Q49783699 | One-year risk of serious infection in patients treated with certolizumab pegol as compared with other TNF inhibitors in a real-world setting: data from a national U.S. rheumatoid arthritis registry |
| Q39009858 | Patients' Experiences of Nurse-Led Screening for Cardiovascular Risk in Rheumatoid Arthritis. |
| Q60952997 | Performance of the Expanded Cardiovascular Risk Prediction Score for Rheumatoid Arthritis in a geographically distant National Register-based cohort: an external validation |
| Q92464625 | Perioperative medical management for patients with RA, SPA, and SLE undergoing total hip and total knee replacement: a narrative review |
| Q93192331 | Prediction of cardiovascular events in rheumatoid arthritis using risk age calculations: evaluation of concordance across risk age models |
| Q36245670 | Predictors of new atherosclerotic carotid plaque development in patients with rheumatoid arthritis: a longitudinal study |
| Q37465556 | Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring: results of an international, cross-sectional study (COMORA). |
| Q38612651 | Prevention of Stroke in Rheumatoid Arthritis |
| Q53502883 | Prevention of stroke in rheumatoid arthritis. |
| Q39082330 | Primary Care Screening and Comorbidity Management in Rheumatoid Arthritis in Ontario, Canada. |
| Q40324538 | Radiographic progression is associated with increased cardiovascular risk in patients with axial spondyloarthritis |
| Q51581221 | Repeat revascularisation outcomes after percutaneous coronary intervention in patients with rheumatoid arthritis. |
| Q40850003 | Response to biological treatment and subsequent risk of coronary events in rheumatoid arthritis |
| Q48008568 | Results from systematic screening for cardiovascular risk in outpatients with rheumatoid arthritis in accordance with the EULAR recommendations |
| Q35957651 | Rheumatoid Arthritis and Incidence of Twelve Initial Presentations of Cardiovascular Disease: A Population Record-Linkage Cohort Study in England |
| Q36001551 | Rheumatoid Arthritis, Anti-Cyclic Citrullinated Peptide Positivity, and Cardiovascular Disease Risk in the Women's Health Initiative |
| Q36812587 | Rheumatoid arthritis and cardiovascular disease: an update on treatment issues |
| Q60592413 | Rheumatoid arthritis is sufficient to cause atheromatosis but not arterial stiffness or hypertrophy in the absence of classical cardiovascular risk factors |
| Q45616855 | Rheumatoid arthritis. Systemic inflammation and cardiovascular morbidity |
| Q35815364 | Risk of atrial fibrillation and stroke in rheumatoid arthritis: Danish nationwide cohort study |
| Q92771595 | Risk of major adverse cardiovascular events among patients with rheumatoid arthritis after initial CT-based diagnosis and treatment |
| Q50561634 | Risk of thromboembolism and fatal stroke in patients with psoriasis and nonvalvular atrial fibrillation: a Danish nationwide cohort study. |
| Q33877737 | Risk of venous thromboembolism in patients with rheumatoid arthritis |
| Q58555310 | Screening of Hyperlipidemia among Patients with Rheumatoid Arthritis in the United States |
| Q40916447 | Subclinical Atherosclerosis in Systemic Sclerosis: Not Less Frequent Than Rheumatoid Arthritis and Not Detected With Cardiovascular Risk Indices |
| Q41514844 | Subcutaneous nodules are associated with cardiovascular events in patients with rheumatoid arthritis: results from a large US registry |
| Q89314644 | Systemic Inflammatory Response and Atherosclerosis: The Paradigm of Chronic Inflammatory Rheumatic Diseases |
| Q41211836 | The 2013 ACC/AHA 10-year atherosclerotic cardiovascular disease risk index is better than SCORE and QRisk II in rheumatoid arthritis: is it enough? |
| Q61797300 | The Use of Rheumatic Disease Comorbidity Index for Predicting Clinical Response and Retention Rate in a Cohort of Rheumatoid Arthritis Patients Receiving Tumor Necrosis Factor Alpha Inhibitors |
| Q44558171 | The association between inflammatory markers, serum lipids and the risk of cardiovascular events in patients with rheumatoid arthritis |
| Q37427394 | The effect of etanercept on traditional metabolic risk factors for cardiovascular disease in patients with rheumatoid arthritis |
| Q37446317 | The risk of atrial fibrillation in patients with rheumatoid arthritis |
| Q36464352 | Traditional cardiovascular risk factors, inflammation and cardiovascular risk in rheumatoid arthritis |
| Q38221011 | Use of DXA-based technology for detection and assessment of risk of vertebral fracture in rheumatology practice |
| Q35754240 | Using epidemiological registry data to provide background rates as context for adverse events in a rheumatoid arthritis drug development program: a coordinated approach. |
| Q35045933 | Utility of different cardiovascular disease prediction models in rheumatoid arthritis |
| Q64086396 | Values and Correlations between C-Reactive Protein and Apolipoprotein B after Treatment with Methotrexate at Patients with Rheumatoid Arthritis |
| Q84815164 | [Cardiovascular comorbidity and its risk factors in rheumatoid arthritis] |
| Q87082709 | [DGRh recommendations for the implementation of current security aspects in the NSAID treatment of musculoskeletal pain] |
Search more.